Chairperson
Byoung Chul Cho, MD, PhD

Professor Byoung Chul Cho is a medical oncologist and Professor in the Division of Medical Oncology at Yonsei Cancer Center, Yonsei University College of Medicine, and Chief of the Lung Cancer Center at Yonsei Cancer Center, Seoul, South Korea. He directs the Yonsei New Il Han Institute for Integrative Cancer Research.

Professor Cho is a world-renowned expert in the field of translational oncology, responsible for 60+ early- to late-phase clinical trials, including over 23 phase 1 clinical trials in the past 3 years alone. He played a pivotal role in the development of repotrectinib, lazertinib, amivantamab, and other targeted and immunotherapies, many of which received breakthrough therapy designation and FDA approval. His Daan Cancer Laboratory focuses on deciphering the immune microenvironment to identify novel immunotherapy targets and design combination strategies, evaluating efficacy of novel cancer therapeutics using patient-derived preclinical models, and understanding resistance mechanisms to targeted therapy in lung cancer.

Professor Cho has authored or co-authored over 250 articles in leading peer-reviewed journals, including Lancet Oncology, Cancer Discovery, Nature Medicine, and The New England Journal of Medicine. He is the recipient of numerous awards for his dedication to cancer research, including the 21^st Wunsch Medical Award, the Boryeong Research Award from the Korean Society of Medical Oncology, the 51st Yuhan Medical Award (Excellence Award), and the 3^rd Yongwoon Medical Award.

Presenter
Rafal Dziadziuszko, MD, PhD

Professor Rafal Dziadziusko is Chair of the Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland.

Professor Dziadziusko completed his MD (1994) and PhD (2003) at the Medical University of Gdansk, subsequently receiving board certifications in radiotherapy (2001) and medical oncology (2004). He completed translational cancer research fellowship at the University of Colorado Cancer Center. Between 2005 and 2007 he worked on predictive assays for EGFR targeted therapies in lung cancer, including immunohistochemistry, gene copy number, and activating mutations. His fellowships were funded by the International Union Against Cancer and the International Association for the Study of Lung Cancer.

Professor Dziadziuszko’s main interests include lung cancer translational and clinical research, and he is a co-author of over 200 peer-reviewed articles. He is a member of the European Society for Radiotherapy and Oncology, European Society for Medical Oncology, International Association for the Study of Lung Cancer, and the European Organisation for Research and Treatment of Cancer – Lung Cancer Group, and is an associate editor of Journal of Thoracic Oncology. He has also participated in the organisation of several academic clinical research studies in Poland and Central Europe and serves as the Vice-Chairman of the Central and East European Oncology Group. In 2017, he received the prestigious Heine H. Hansen Award for global contribution to lung cancer research and care, and in 2023, the James Cox Award for contribution to international research on radiotherapy of lung cancer.

Presenter
Lucksamon Thamlikitkul, MD, PhD

Dr Lucksamon Thamlikitkul is an Instructor in the Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, and Consultant Medical Oncologist with the Cancer Center, Siriraj Piyamaharajkarun Hospital, Bangkok, Thailand. Concurrently, he serves as Secretary and Board Member of the Siriraj Cancer Center, and Board Member of the Siriraj Metabolomics and Phenomics Center.

Dr Lucksamon earned his MD (first class honours) from the Faculty of Medicine Siriraj Hospital, Mahidol University in 2010, then subsequently underwent internal medicine residency training at the Faculty of Medicine, Prince of Songkla University, followed by medical oncology fellowship training at the Faculty of Medicine Siriraj Hospital, Mahidol University. Thereafter, Dr Lucksamon obtained his MSc (Cancer) from University College London in 2018, and his PhD from the Division of Cancer, Department of Surgery and Cancer, Imperial College London in 2021.

Dr Lucksamon is a member of the Thai Society of Clinical Oncology (TSCO), the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), the American Association for Cancer Research, the European Association for Cancer Research, the International Association for the Study of Lung Cancer, and the Royal College of Physicians of Thailand. He is increasingly being recognized for his clinical and academic oncology work, receiving the International Development and Education Award from ASCO in 2017, the Best Research Award from TSCO in 2016, and participation in the ESMO Leader Generation Programme Asia in 2022.